Immuneering Corporation clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   IMM-1-104 · Advanced or Metastatic Solid Tumors

   Primary completion pushed from Jun 2026 to Jun 2027

   Also in this update: Study completion pushed from Jun 2027 to Jun 2028

   Immuneering Corporation·Phase 1/2· NCT05585320· Registry history of NCT05585320 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.